SCHEMBL4433924

SCHEMBL4433924

CCOc1ccccc1C(=O)Nc1ccccc1C

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.74
GAA P10253 3/20 0.74
MAPK1 P28482 2/20 0.74
L3MBTL1 Q9Y468 3/20 0.69
ALDH1A1 P00352 2/20 0.69
KCNMA1 Q12791 2/20 0.66
RXFP1 Q9HBX9 2/20 0.64
TP53 P04637 3/20 0.64
MEN1 O00255 3/20 0.63
KMT2A Q03164 3/20 0.63
HCRTR1 O43613 1/20 0.61
TSHR P16473 2/20 0.61
HPGD P15428 2/20 0.61
NPSR1 Q6W5P4 2/20 0.61
HSD17B10 Q99714 2/20 0.61
LMNA P02545 2/20 0.61
KDM4E B2RXH2 1/20 0.61
ATM Q13315 1/20 0.61
USP2 O75604 1/20 0.61
ALOX15 P16050 1/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24469708 0.88 MAPT (0.63) MAPTGAAMAPK1L3MBTL1ALDH1A1
SCHEMBL11600983 0.88 MAPT (0.70) MAPTGAAMAPK1L3MBTL1ALDH1A1
SCHEMBL15323115 0.88 GAA (0.78) MAPTGAAMAPK1L3MBTL1ALDH1A1
SCHEMBL7165819 0.86 MAPT (0.63) MAPTGAAMAPK1L3MBTL1ALDH1A1
SCHEMBL328592 0.85 GAA (0.74) MAPTGAAMAPK1L3MBTL1ALDH1A1
SCHEMBL15528654 0.84 MAPT (0.74) MAPTGAAMAPK1L3MBTL1ALDH1A1
SCHEMBL14224949 0.82 NPC1 (0.66) MAPTGAAL3MBTL1ALDH1A1MEN1
SCHEMBL11005738 0.82 KMT2A (0.66) MAPTGAAL3MBTL1ALDH1A1MEN1
SCHEMBL11891753 0.82 MAPT (0.69) MAPTGAAMAPK1L3MBTL1ALDH1A1
SCHEMBL5504642 0.80 MEN1 (0.83) MAPTGAAMAPK1L3MBTL1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9447027-B2 Treating long QT syndrome THE GENERAL HOSPITAL CORPORATION (US) 2016-09-20 US disclosed
US-9447027-B2 Treating long QT syndrome THE GENERAL HOSPITAL CORPORATION (US) 2016-09-20 US disclosed
US-20130310351-A1 Treating Long QT Syndrome THE GENERAL HOSPITAL CORPORATION (US) 2013-11-21 US disclosed
WO-2012054718-A2 TREATING LONG QT SYNDROME THE GENERAL HOSPITAL CORPORATION (US) 2012-04-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130310351-A1 Treating Long QT Syndrome TNNI3, TNNT2, TNNC1 MAPT 3780/4885GAA 663/4885MAPK1 3036/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.